Evexta Bio and Roche Partner to Evaluate Rupitasertib Combination in Advanced Breast Cancer
PARIS, Aug. 4, 2026 Evexta Bio announced a clinical trial collaboration and supply agreement with Roche to evaluate its...
Phase 1b
Advertisement
MannKind Reports Positive Phase 1b INFLO-1 IPF Results
Danbury, Conn. & Westlake Village, Calif., July 29, 2026 MannKind Corporation announced positive topline results from its Phase 1b...
Oncotelic Publishes Deciparticle Data Supporting Sapu003 Clinical Trial
Agoura Hills, Calif., July 22, 2026 Oncotelic Therapeutics and Sapu Nano announced the publication of a peer-reviewed study in...
ProMIS Reports First Human PMN310 Evidence
CAMBRIDGE, Mass., July 14, 2026 ProMIS Neurosciences presented the first human evidence that its investigational Alzheimer’s disease therapy PMN310...
Kura Oncology Presents Darlifarnib Plus Cabozantinib Data
SAN DIEGO, July 14, 2026 Kura Oncology announced that updated long-term follow-up data from the ongoing FIT-001 Phase 1a...
Advertisements
Agenus Reports Three-Year BOT+BAL Survival Data
LEXINGTON, Mass., July 6, 2026 Agenus announced new three-year follow-up results from the fully enrolled Phase 1b C-800-01 study...
Kenai Therapeutics Completes Phase 1b/2a REPLACE Trial Enrollment
SAN DIEGO, July 7, 2026 Kenai Therapeutics has announced the successful completion of patient enrollment in the Phase 1b/2a...
AnaCardio Publishes AC01 Heart Failure Study in The Lancet
STOCKHOLM, Sweden, June 25, 2026 AnaCardio announced that results from its Phase 1b/2a GOAL-HF1 clinical trial evaluating AC01, a...
Cambrian Bio Reports Positive Phase 1b ATX-304 Data
NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...
TuHURA Files IND for TBS-2025 in AML and Blood Cancers
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
Advertisement
